Why Pet Dogs May Get the First Drug Approved to Extend Lifespan

This article is educational. It is not medical or veterinary advice and does not recommend any treatment, drug, or product.

The first medicine ever labeled to extend the life of a healthy animal may be prescribed by a veterinarian before any doctor can offer anything similar to a person. Large trials in pet dogs are testing whether slowing aging itself, rather than curing one disease at a time, can add healthy years. This page covers that research because it is a concrete piece of longevity futurism: if companion dogs can show that aging responds to a drug in a few years instead of a few decades, it becomes easier to argue that healthy time is something humans can make more of, which is a step from scarcity of healthy years toward abundance.

The problem with testing aging drugs in people

Aging is the largest single risk factor for heart disease, cancer, dementia, and frailty, yet drug rules in the United States are built around specific diseases. The Food and Drug Administration does not currently recognize aging as a treatment indication, as researchers writing about the proposed Targeting Aging with Metformin (TAME) trial have noted. That trial was designed in consultation with the agency so that a delay in a group of age related diseases could stand in for "slowing aging," because there was no other accepted way to measure success.

Even with a workable design, a human aging trial runs into time. People live for decades, so a study that waits to see who lives longer would outlast careers, grants, and patents. Mice live only a few years, which makes them fast to study, but they live in cages, eat one controlled diet, and share very similar genes. A result in a lab mouse often fails to carry over to a person who lives in a messy, varied world. For more on why these gaps exist, see Classifying aging.

Why pet dogs are a useful middle step

Pet dogs sit between mice and people. They live long enough to develop many of the same diseases humans do, including heart disease, cancer, arthritis, kidney decline, and cognitive decline, but their whole lifespan is short enough that a trial can follow older dogs to the end of life within a few years. They also share homes, air, water, and sometimes food habits with their owners, and they vary widely in breed, size, and genetics. Those differences make dog results harder to collect than mouse results, but closer to the real conditions a human drug would face.

There is also an old proof that dog aging can be changed. In a study published in 2002, researchers paired 48 Labrador Retrievers and fed one dog in each pair 25 percent less food than its partner from eight weeks of age until death. The leaner dogs had a median lifespan of 13.0 years compared with 11.2 years for the control dogs, and the onset of chronic disease was generally delayed. Few owners would feed a dog that strictly for life, but the study showed that aging in a large mammal can move, which is the premise behind the drug trials below.

Two large trials now underway

The rapamycin trial in older dogs

The Dog Aging Project is a community science effort led by Texas A&M University, the University of Washington, and Tufts University, with other collaborators. Its main observational study follows more than 50,000 dogs through owner surveys. Inside it sits a smaller clinical trial called the Test of Rapamycin in Aging Dogs, or TRIAD.

Rapamycin is a drug used at high doses to suppress the immune system after organ transplants. At low doses it changes how cells handle energy and growth by acting on a pathway called mTOR, and it has been described as one of the most promising agents against aging identified in laboratory research. In TRIAD, dogs at least seven years old and between 44 and 120 pounds receive a once weekly low dose of rapamycin or a placebo for one year, followed by two more years of checkups. Neither owners nor most researchers know which dogs got the real drug. The main question is whether treated dogs live longer, and secondary questions cover heart, brain, kidney, and joint health.

The project describes the trial as the first rigorous test of a drug against biological aging, with lifespan and healthspan as endpoints, carried out outside a laboratory in any species. Its funding has been fragile. The original 2019 grant from the National Institute on Aging was not renewed in 2024, and the trial continued on a separate five year grant of about 7 million dollars. As of a spring 2026 recruitment letter, 266 dogs had enrolled toward a goal of 580, and 52 had finished the full three years. The trial is scheduled to end in November 2029.

A company trial in senior dogs

A private veterinary drug company called Loyal is running the STAY study for a daily tablet called LOY-002, aimed at dogs aged 10 and older that weigh at least 14 pounds. The company describes it as a double blind, placebo controlled study of about 1,300 dogs at roughly 70 veterinary clinics, lasting about four years, with the first dog dosed in December 2023 and enrollment completed in July 2025. The drug is meant to target metabolic decline, the same broad mechanism that the food restriction study pointed to.

The regulatory path is the most surprising part. Animal drugs in the United States can receive conditional approval if they show a reasonable expectation of effectiveness, meet full safety and manufacturing standards, and keep collecting proof afterward. In February 2025 the company announced that the agency had accepted its effectiveness section for lifespan extension in senior dogs, and in January 2026 it announced acceptance of its safety section. The manufacturing section was still in progress, with review expected in 2027. None of these steps is approval, and no lifespan result from STAY has been published.

Why this matters for human longevity

If either trial shows that a drug lets ordinary pet dogs live longer and healthier lives, three things change.

Aging becomes a target in law, not just in theory. A drug labeled for lifespan extension in any species would give regulators, insurers, and lawmakers a real example to point to when humans ask for the same.
Real world trial design gets tested. Dog trials run through ordinary clinics and home dosing, which is close to how a human prevention drug would be used. Lessons about recruitment, dropout, and measurement can be reused.
The cost of proof falls. A trial that answers a lifespan question in four years costs far less than one that takes thirty. Lower cost of evidence means more ideas can be tested, which is how abundance in any field tends to start.

A negative result would also be useful. If low dose rapamycin fails to extend life in dogs, money and attention can move to other approaches sooner, as discussed in Anti-aging research.

Honest limits

Dogs are not small humans. Their metabolism, cancer patterns, and drug handling differ, and a dose that helps one species may harm another. Both trials are still running, and no published result yet shows that either drug extends a dog's life. Company announcements describe a developer's own progress and should be weighed against independent review once full data appear. Regulatory milestones for animal drugs do not create a human pathway, and a human trial would still need its own evidence. Rapamycin carries real risks at higher doses in people, and nothing here supports taking it, giving it to a pet outside a supervised study, or buying any longevity product. For a way to judge claims in this area, see Evaluating anti-aging claims.

Discussion questions, essay ideas, and learning related AI prompt ideas

Explain why a drug approved to extend the lifespan of dogs might change how regulators think about aging drugs for people.
Compare the strengths and weaknesses of mice, pet dogs, and humans as subjects for aging research.
Describe what the 2002 Labrador Retriever food restriction study shows and what it cannot show about human aging.
Discuss whether pet owners who enroll their dogs in aging trials are doing a form of citizen science that benefits humans and animals together.
Consider how unstable grant funding affects long trials like TRIAD and what other ways of paying for them could work.
Outline what evidence would be needed before a result in dogs should change any decision about human medicine.
Explore how lower cost evidence about aging could move society from a scarcity of healthy years toward an abundance of them.

References

Dog aging trials as a shortcut for human longevity

Contents